AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Study NCT03711214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal scaling
Description: Periodontal scaling and root planing
Study NCT00985608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A: NCA 600 mg+antibiotics
Description: NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
Study NCT00985608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B: antibiotic treatment (control)
Description: patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
Study NCT03470194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Modality: In Person
Description: Use of In-Person interpretation support for LEP participant during clinical appointment
Study NCT03470194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Modality: Telephonic
Description: Use of telephonic interpretation support for LEP participant during clinical appointment
Study NCT02963363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Adapted Physical Activity
Description: Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks
Study NCT01038479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol consumption
Description: Mothers will eat 6 grams of xylitol per day
Study NCT01038479 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Childsmile preventative programme
Description: Mothers will receive the childsmile preventative programme
Study NCT01038479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Childsmile preventative programme
Description: Mothers will receive the childsmile preventative programme
Study NCT01764269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: text message surveillance for fever
Study NCT03694340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Re-programming of cochlear implant
Description: New MAP based on behavioral T- and C-levels
Study NCT01109121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 400
Description: Tranilast 300 mg QD; Allopurinol 400 mg QD
Study NCT01109121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 400 mg, QD
Study NCT01109121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 600
Description: Tranilast, 300 mg QD; Allopurinol 600 mg QD
Study NCT01157572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
Study NCT01157572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
Study NCT00104416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (LAMICTAL) extended-release
Description: Primary experimental dosage form
Study NCT00104416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT02250794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and sitagliptin
Description: metformin 750 mg PO twice daily
Study NCT02250794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine and insulin lispro
Description: insulin glargine given once daily
Study NCT02250794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and sitagliptin
Description: sitagliptin 100 mg PO once daily
Study NCT02250794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine and insulin lispro
Description: insulin lispro given three times daily with meals
Study NCT03322046 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle Program
Description: 4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
Study NCT05336929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roy adaptation model-based nursing education
Study NCT01295840 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: Cardiac Resynchronization Therapy Defibrillator
Study NCT04400019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Only Product in Oral Dose Form
Description: The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
Study NCT04016285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys
Description: The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval
Study NCT04016285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: Standard of care for reducing bleeding during the total knee arthroplasty
Study NCT03716024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 0796
Description: PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
Study NCT03716024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
Study NCT00783003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
Study NCT00783003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Inhaled Long acting Beta 2 agonist (LABA)
Study NCT00783003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
Study NCT00783003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study NCT02931487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: Computerized
Study NCT02931487 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Computerized
Study NCT00284050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Description: 6 mg/ml ranibizumab solution for intravitreal injection
Study NCT00284050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: 10 mg/ml ranibizumab solution for intravitreal injection
Study NCT00284050 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Non-treatment control for sham intravitreal injection.
Study NCT04346602 — intervention group
Intervention type: OTHER
Intervention: all treatment about COVID-2019
Description: All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
Study NCT04571138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CAR22v2
Description: Single infusion of SCRI-CAR22v2
Study NCT02093832 — intervention group
Intervention type: OTHER
Intervention: There are no specific Intervention
Description: are no specific Intervention
Study NCT03763253 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
Study NCT03763253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Ablative Therapy (MIAT)
Description: MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use.
Study NCT03763253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Therapy (Prostatectomy or Radiotherapy)
Description: Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use.
Study NCT01569789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulator
Description: Voltage 2, placed on cymba concha
Study NCT01569789 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vagus Nerve Stimulator
Description: Voltage 2, place on the placebo area of the calf
Study NCT01170858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin PD solution
Description: 2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
Study NCT01170858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose solutions
Study NCT01502059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates training - twice a week (one hour per class) during 90 days
Study NCT03258021 — intervention group
Intervention type: DEVICE
Intervention: TTFields
Description: Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
Study NCT02573350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
Study NCT02573350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBR
Description: Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study NCT01811160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: A capsule of melatonin was administered nightly (20:00hrs).
Study NCT01811160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were administered at 20:00hrs for eight weeks
Study NCT00958152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
Study NCT00958152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
Study NCT04511455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg/day peroral
Study NCT00958152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
Study NCT00958152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 1125 mg, q12h, Days 18-37
Study NCT02083718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC
Study NCT02083718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study NCT03456453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDA Standard for HIV Prevention
Description: The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
Study NCT04960033 — intervention group
Intervention type: BEHAVIORAL
Intervention: FRAX
Description: The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
Study NCT04579705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using a brush
Description: Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HpSA (Firstep Helicobacter pylori Antigen Rapid Test)
Description: HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT only
Description: HPSA+FIT compared with FIT alone.
Study NCT01218490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cancer surgery
Study NCT01782846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixprim®
Study NCT01782846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dafalgan-Codeine®
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield in the presence of a non-UV absorbing block.
Description: The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield in the presence of a UV absorbing block.
Description: The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield
Description: The psoriashield will be applied to patient's back.
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac laser in the presence of a non-UV absorbing block.
Description: The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac in the presence of a UV absorbing block.
Description: The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
Study NCT03049319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac laser
Description: The Xtrac laser will be applied to patient's back.
Study NCT01850251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with HMB and vitamin D
Description: High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
Study NCT01850251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional supplement
Description: High protein, high calorie nutritional supplement.
Study NCT01915758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin1%/tretinoin 0.025% gel
Description: clindamycin1%/tretinoin 0.025% gel
Study NCT01915758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: vehicle gel
Study NCT01197144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Subcutaneous, 40 mg every other week for 4 weeks
Study NCT01197144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous, every other week for 4 weeks
Study NCT02333825 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Medial patellofemoral ligament reconstruction surgery
Description: Medial patellofemoral ligament reconstruction surgery using hamstring autograft
Study NCT02333825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy and rehabilitation
Description: A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
Study NCT04715828 — intervention group
Intervention type: OTHER
Intervention: Cryopreserved semen
Description: sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
Study NCT04715828 — intervention group
Intervention type: OTHER
Intervention: Acute and low irradiation
Description: sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
Study NCT04715828 — intervention group
Intervention type: OTHER
Intervention: Long and low irradiation
Description: sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
Study NCT04715828 — intervention group
Intervention type: OTHER
Intervention: Long and medium irradiation
Description: sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
Study NCT01253694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 0.5 mg of Intravitreal Ranibizumab
Description: Following the sterile technique, intravitreal injection of anti-VEGF is applied
Study NCT01981031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Study NCT01981031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Study NCT01577524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
Study NCT01577524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
Study NCT02845466 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Becaplermin
Description: 0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
Study NCT02845466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Becaplermin
Description: 0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
Study NCT02845466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promagran Dressing
Description: 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
Study NCT02845466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Dressing
Description: Inactive wound dressing.
Study NCT01262963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
Study NCT01596231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu
Description: Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
Study NCT01596231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
Study NCT03676413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
Description: new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
Study NCT03676413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
Description: twice daily inhalation throughout the study